|
| 36223558 | Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. | J Clin Oncol | 2023 |
| 37468498 | A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs. | Nat Commun | 2023 |
| 36725084 | First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. | J Immunother Cancer | 2023 |
| 34648948 | First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. | J Thorac Oncol | 2022 |
| 33082101 | Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation. | Clin Lung Cancer | 2021 |
| 33791693 | Phospholipidosis is a shared mechanism underlying the in vitro antiviral activity of many repurposed drugs against SARS-CoV-2. | bioRxiv | 2021 |
| 33483756 | Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes. | Toxicol Sci | 2021 |
| 35002544 | Increase in the Length of Lung Cancer Patient Pathway Before First-Line Therapy: A 6-Year Nationwide Analysis From Hungary. | Pathol Oncol Res | 2021 |
| 34406891 | Formation of a novel supraspinal-spinal connectome that relearns the same motor task after complete paralysis. | J Neurophysiol | 2021 |
| 34326236 | Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. | Science | 2021 |
| 32565027 | Machine learning guided association of adverse drug reactions with in vitro target-based pharmacology. | EBioMedicine | 2020 |
| 32703874 | The activities of drug inactive ingredients on biological targets. | Science | 2020 |
| 32872120 | Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, <i>ALK</i>-Positive, <i>TP53</i>-Mutant NSCLC. | J Pers Med | 2020 |
| 32340676 | Lung Cancer in Hungary. | J Thorac Oncol | 2020 |
| 30244081 | Safety differentiation: emerging competitive edge in drug development. | Drug Discov Today | 2019 |
| 27557833 | Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. | Support Care Cancer | 2017 |
| 28461256 | Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer. | J Thorac Oncol | 2017 |
| 28794167 | REPLY TO THORNELOE ET AL. | Physiol Rev | 2017 |
| 28786378 | Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets. | Elife | 2017 |
| 27803064 | Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer. | Clin Cancer Res | 2017 |
| 26975508 | Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and Mitigation. | Curr Top Med Chem | 2016 |
| 27653550 | Spatial Distribution of the Cannabinoid Type 1 and Capsaicin Receptors May Contribute to the Complexity of Their Crosstalk. | Sci Rep | 2016 |
| 27140035 | Secondary pharmacology: screening and interpretation of off-target activities - focus on translation. | Drug Discov Today | 2016 |
| 27252279 | TRPV4: Molecular Conductor of a Diverse Orchestra. | Physiol Rev | 2016 |
| 26022402 | Integrated risk assessment of suicidal ideation and behavior in drug development. | Drug Discov Today | 2015 |
| 26272769 | Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. | Lancet Oncol | 2015 |
| 26272768 | Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. | Lancet Oncol | 2015 |
| 24192513 | Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. | Lung Cancer | 2014 |
| 24802392 | A screening pattern recognition method finds new and divergent targets for drugs and natural products. | ACS Chem Biol | 2014 |
| 24283624 | Transient receptor potential ion channels in primary sensory neurons as targets for novel analgesics. | Br J Pharmacol | 2014 |
| 22722194 | Large-scale prediction and testing of drug activity on side-effect targets. | Nature | 2012 |
| 20932250 | Molecular structure of transient receptor potential vanilloid type 1 ion channel (TRPV1). | Curr Pharm Biotechnol | 2011 |
| 22050465 | Computational methods for early predictive safety assessment from biological and chemical data. | Expert Opin Drug Metab Toxicol | 2011 |
| 21561375 | IonFlux: a microfluidic patch clamp system evaluated with human Ether-Ã -go-go related gene channel physiology and pharmacology. | Assay Drug Dev Technol | 2011 |
| 21742496 | The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors. | Bioorg Med Chem Lett | 2011 |
| 21650221 | Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. | J Med Chem | 2011 |
| 21153723 | Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response. | Pathol Oncol Res | 2011 |
| 20932253 | TRPV1 function in health and disease. | Curr Pharm Biotechnol | 2011 |
| 20179512 | Role of transient receptor potential and acid-sensing ion channels in peripheral inflammatory pain. | Anesthesiology | 2010 |
| 21133679 | Cardiac ion channel safety profiling on the IonWorks Quattro automated patch clamp system. | Assay Drug Dev Technol | 2010 |
| 20631060 | High-content micronucleus assay in genotoxicity profiling: initial-stage development and some applications in the investigative/lead-finding studies in drug discovery. | Toxicol Sci | 2010 |
| 20154663 | Phenotypic screening: Fishing for neuroactive compounds. | Nat Chem Biol | 2010 |
| 19378990 | Mapping adverse drug reactions in chemical space. | J Med Chem | 2009 |
| 21426031 | In vitro safety pharmacology profiling: what else beyond hERG? | Future Med Chem | 2009 |
| 19779217 | The accuracy of EGSnrc, Geant4 and PENELOPE Monte Carlo systems for the simulation of electron scatter in external beam radiotherapy. | Phys Med Biol | 2009 |
| 19434832 | Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. | J Chem Inf Model | 2009 |
| 18474896 | Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery. | J Biomol Screen | 2008 |
| 17492703 | Modeling promiscuity based on in vitro safety pharmacology profiling data. | ChemMedChem | 2007 |
| 17916053 | Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. | Expert Opin Drug Metab Toxicol | 2007 |
| 18019783 | [Fixed-dose combinations in the first line of antihypertensive therapy]. | Acta Pharm Hung | 2007 |